TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34328776

Group type: EXPERIMENTAL
Intervention: Derandomized measurement procedure using fixed Pauli measurements on quantum states.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized measurement procedure using random single-qubit measurements.
Number of subjects: 0
Study: 32993094

Group type: EXPERIMENTAL
Intervention: Straight Leg Raise test and Bragard test performed in a multiple parallel way
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Combined test of the Slump test and Dejerine’s triad
Number of subjects: 864
Study: 35014615

Group type: EXPERIMENTAL
Intervention: Pidotimod (n=35)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (n=35)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups (pidotimod and placebo)
Number of subjects: 79
Study: 33715892

Group type: EXPERIMENTAL
Intervention: Vigil (Gemogenovatucel-T)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 32108976

Group type: EXPERIMENTAL
Intervention: I Can PIC
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control (attention control health insurance worksheet)
Number of subjects: 263
Study: 35090540

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine e-aid Cognitive Behavioral Therapy for Insomnia (TCM-eCBT-I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with TCM-eCBT-I
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 33990151

Group type: EXPERIMENTAL
Intervention: Mendelsohn maneuver and swallowing training
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group (health education, psychological intervention, and training of the oral muscle group)
Number of subjects: 214
Study: 33217717

Group type: EXPERIMENTAL
Intervention: Aerie campaign
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Dove campaign
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Victoria's Secret campaign
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: HBO documentary
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control (neutral video clip)
Number of subjects: 475
Study: 35617368

Group type: EXPERIMENTAL
Intervention: ZF2001 (1 dose) administered at 28 days after priming, followed by ZF2001 at 5 months (CV/ZF/ZF D0-D28-M5)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ZF2001 (1 dose) administered at 56 days after priming, followed by ZF2001 at 6 months (CV/ZF/ZF D0-D56-M6)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CV/ZF (D0-M5)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CV/ZF (D0-M6)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TIV (trivalent inactivated influenza vaccine)
Number of subjects: 120
Study: 33600441

Group type: EXPERIMENTAL
Intervention: Negative Affect (NA) condition
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Positive Affect (PA) condition
Number of subjects: 126

Group type: COMPARATOR
Intervention: No affect change (control) condition
Number of subjects: 126
Study: 33111942

Group type: EXPERIMENTAL
Intervention: Low-dose NGF (1 µg) injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control injections of isotonic saline
Number of subjects: 20
Study: 36429962

Group type: EXPERIMENTAL
Intervention: Integral‐CARE Interdisciplinary Program (IP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 32808423

Group type: EXPERIMENTAL
Intervention: Motivational support programme (including motivational interviews, reminder messages, and education programmes for parents) over a 6-month period
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Motivational support programme
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (routine follow-ups)
Number of subjects: 64
Study: 32173046

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatments followed by radical surgery (NTS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard chemoradiation (CRT)
Number of subjects: 90
Study: 32757634

Group type: EXPERIMENTAL
Intervention: Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 36310089

Group type: EXPERIMENTAL
Intervention: Beetroot juice with 380 mg of nitrate (BR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beetroot juice placebo (PL)
Number of subjects: 0
Study: 36311889

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 48
Study: 35179334

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Square Dance
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control
Number of subjects: 144
Study: 33197676

Group type: EXPERIMENTAL
Intervention: Cupping Therapy (CT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vigorous Exercise (VE)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cupping plus Vigorous Exercise (VECT)
Number of subjects: 21
Study: 33821768

Group type: EXPERIMENTAL
Intervention: FDC IBU/APAP
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1477
Study: 32804144

Group type: COMPARATOR
Intervention: MCI Aβ+ individuals
Number of subjects: 261

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 261

Group type: COMPARATOR
Intervention: MCI Aβ+ and MCI Aβ- individuals
Number of subjects: 261
Study: 36350082

Group type: EXPERIMENTAL
Intervention: 50 g prunes per day
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Prune treatments (50 g and 100 g)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Prunes (50 g and 100 g)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Prunes
Number of subjects: 143
Study: 33475255

Group type: EXPERIMENTAL
Intervention: JNJ-64565111 5.0 mg
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: JNJ-64565111 7.4 mg
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: JNJ-64565111 10.0 mg
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 474

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study: 32824958

Group type: EXPERIMENTAL
Intervention: Higher maternal total 25(OH)D concentrations
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Higher maternal free 25(OH)D concentrations
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Higher total 25(OH)D concentrations
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Higher VDBP concentrations
Number of subjects: 304
Study: 35410294

Group type: EXPERIMENTAL
Intervention: Multimodal intervention care (MIC) including ibuprofen, omega‐3‐fatty acid, oral nutritional supplement, weekly physical, psychiatric assessment, nutritional counseling, and complementary and alternative medicine.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional palliative care (CPC) including basic nutritional counseling and megestrol acetate as needed.
Number of subjects: 112
Study: 33468454

Group type: EXPERIMENTAL
Intervention: tDCS added to a 2-week camp-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Camp-based therapy alone
Number of subjects: 0
Study: 32343308

Group type: EXPERIMENTAL
Intervention: 1 μg/ml of sufentanil plus 2.5 μg/ml of DEX (Group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 μg/ml of sufentanil (Group S)
Number of subjects: 60
Study: 35451378

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion (AM)
Number of subjects: 0
Study: 32873496

Group type: EXPERIMENTAL
Intervention: Video conferencing telehealth (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Telephone-only telehealth (n = 30)
Number of subjects: 60
Study: 35732348

Group type: EXPERIMENTAL
Intervention: adagloxad simolenin/OBI‐821
Number of subjects: 349
Study: 34082019

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 592

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 592
Study: 32170194

Group type: EXPERIMENTAL
Intervention: Male voice alarm
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Female voice alarm
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Hybrid alarm (low-frequency tone + female voice)
Number of subjects: 188

Group type: COMPARATOR
Intervention: High-frequency tone alarm
Number of subjects: 188
Study: 35904229

Group type: EXPERIMENTAL
Intervention: Volume-stable collagen matrix (VCMX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue grafts (SCTG)
Number of subjects: 20
Study: 33522902

Group type: EXPERIMENTAL
Intervention: Client reminder designed based on nudge theory principles (Group A)
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Fully subsidized screening with nudge theory (Group B)
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Control group (no nudge theory)
Number of subjects: 1496
Study: 32478849

Group type: EXPERIMENTAL
Intervention: In-person navigator intervention
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Active control (written resources handout)
Number of subjects: 1300
Study: 33855207

Group type: EXPERIMENTAL
Intervention: Combined use of metformin, SGLT2 inhibitor, GLP1 receptor agonist, and basal insulin (step-down approach)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 22
Study: 32846549

Group type: EXPERIMENTAL
Intervention: Nutritional warnings
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Health logos
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Control (no information)
Number of subjects: 1232
Study: 35101139

Group type: EXPERIMENTAL
Intervention: HMB supplementation (3 grams dissolved in 150 ml of orange juice or water)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (150 ml of orange juice or water)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33959800

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine
Number of subjects: 71

Group type: COMPARATOR
Intervention: saline control
Number of subjects: 71
Study: 32822130

Group type: EXPERIMENTAL
Intervention: Regional Anesthesia (RA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 106
Study: 35107563

Group type: EXPERIMENTAL
Intervention: Isoproterenol 0.5 μg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 58
Study: 32669672

Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study: 33027534

Group type: EXPERIMENTAL
Intervention: Advanced recovery room care for 12–18 hours postoperatively in the post-anaesthesia care unit.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Advanced recovery room care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard postoperative ward care (implied control)
Number of subjects: 120
Study: 33046475

Group type: EXPERIMENTAL
Intervention: Power training programme using elastic devices (elastic bands and tubes), 12-week intervention, 2 sessions per week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Health education programme, 12-week intervention, 1 session per week
Number of subjects: 50
Study: 616796537

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training and impact loading programme for 8 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Machine-based isometric exercise training programme using the bioDensity system for 8 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training and impact loading programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Machine-based isometric exercise training programme using the bioDensity system
Number of subjects: 0
Study: 36367983

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 288
Study: 33896655

Group type: EXPERIMENTAL
Intervention: Comb-Simple model
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Comb-LR model
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Comb-RDT model
Number of subjects: 509

Group type: COMPARATOR
Intervention: Mini-Cog
Number of subjects: 509

Group type: COMPARATOR
Intervention: Fototest
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Two-step application
Number of subjects: 509
Study: 32557643

Group type: EXPERIMENTAL
Intervention: Therapeutic monoclonal antibodies (mAbs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose pharmacokinetic model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariable analysis and/or case control analysis
Number of subjects: 0
Study: 36457124

Group type: EXPERIMENTAL
Intervention: PDT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% NaClO
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% NaClO + PDT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study: 34759549

Group type: EXPERIMENTAL
Intervention: Caudal epidural block with 0.75 mL.kg ‐1 of 0.25% bupivacaine and 1 mcg.kg ‐1 of dexmedetomidine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ilioinguinal-iliohypogastric block with 0.25 mL.kg ‐1 of 0.25% bupivacaine and 1 mcg.kg ‐1 of dexmedetomidine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both interventions (caudal and IL/IH blocks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Caudal block
Number of subjects: 46

Group type: COMPARATOR
Intervention: IL/IH block
Number of subjects: 46
Study: 35293484

Group type: EXPERIMENTAL
Intervention: Breath stacking technique (BS) associated with routine physiotherapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional physiotherapy only (Control Group)
Number of subjects: 34
Study: 32063417

Group type: EXPERIMENTAL
Intervention: Stump Cylinder
Number of subjects: 95

Group type: COMPARATOR
Intervention: custom mold
Number of subjects: 95
Study: 35293256

Group type: EXPERIMENTAL
Intervention: New birthing room with adaptable physical features
Number of subjects: 202
Study: 33570787

Group type: EXPERIMENTAL
Intervention: 6 mm implants alone (Group 1)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 8 mm implants + OSFE (Group 2)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 10 mm implants + OSFE (Group 3)
Number of subjects: 225

Group type: COMPARATOR
Intervention: 6 mm implants (Group 1)
Number of subjects: 225
Study: 35595677

Group type: EXPERIMENTAL
Intervention: 63 ACE indicators across six domains (maternal mental health problems, maternal substance misuse, adverse family environments, child maltreatment, maternal IPV, high-risk presentations of child maltreatment)
Number of subjects: 211393

Group type: EXPERIMENTAL
Intervention: 63 ACE indicators
Number of subjects: 211393

Group type: EXPERIMENTAL
Intervention: Maternal mental health problems
Number of subjects: 211393

Group type: EXPERIMENTAL
Intervention: Adverse family environments
Number of subjects: 211393

Group type: EXPERIMENTAL
Intervention: High-risk presentations of child maltreatment
Number of subjects: 211393

Group type: EXPERIMENTAL
Intervention: Maternal substance misuse
Number of subjects: 211393

Group type: EXPERIMENTAL
Intervention: Any child maltreatment
Number of subjects: 211393

Group type: EXPERIMENTAL
Intervention: Maternal IPV
Number of subjects: 211393
Study: 35590301

Group type: EXPERIMENTAL
Intervention: High caries group (≥ 5 decayed surfaces)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Caries group (2-4 decayed surfaces)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 34535520

Group type: EXPERIMENTAL
Intervention: Opioid pain medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-opioid pain medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain prescriptions
Number of subjects: 0
Study: 35764103

Group type: EXPERIMENTAL
Intervention: 20-30% SF6 gas tamponade (Group A)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS) (Group B)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study: 34430405

Group type: EXPERIMENTAL
Intervention: Individualized psychological intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 32737104

Group type: COMPARATOR
Intervention: PsA (model0)
Number of subjects: 5748

Group type: COMPARATOR
Intervention: PsA (model1)
Number of subjects: 5748

Group type: COMPARATOR
Intervention: PsA (model2)
Number of subjects: 5748

Group type: COMPARATOR
Intervention: Psoriasis without arthritis
Number of subjects: 5748

Group type: COMPARATOR
Intervention: Genetically determined psoriasis/PsA
Number of subjects: 5748

Group type: COMPARATOR
Intervention: MR analysis
Number of subjects: 5748
Study: 35484990

Group type: EXPERIMENTAL
Intervention: CDP‐choline (5 mg/kg in 0.1 mL/kg 0.9% saline, IV; n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vehicle (0.1 mL/kg sterile 0.9% saline, IV; n=8)
Number of subjects: 17
Study: 34435426

Group type: EXPERIMENTAL
Intervention: Shoulder MRA
Number of subjects: 200
Study: 32597287

Group type: EXPERIMENTAL
Intervention: Plantar vibration stimuli for 2 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham interventions
Number of subjects: 16
Study: 35329361

Group type: EXPERIMENTAL
Intervention: Low-Fat Chocolate Milk (LFCM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 7
Study: 35803302

Group type: EXPERIMENTAL
Intervention: Ventilatory strategy to prevent atelectasis (VESPA) with endotracheal intubation, recruitment maneuver, FIO2 titration (< 100%), and PEEP of 8 to 10 cm H2O.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard ventilation (laryngeal mask airway, 100% FIO2, zero PEEP).
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ventilatory strategy to prevent atelectasis (VESPA).
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard ventilation (control group).
Number of subjects: 76
Study: 34046861

Group type: EXPERIMENTAL
Intervention: NOACs (apixaban, rivaroxaban, dabigatran)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 29

Group type: COMPARATOR
Intervention: VKAs (age-matched and sex-matched controls)
Number of subjects: 29

Group type: COMPARATOR
Intervention: VKAs (historical controls)
Number of subjects: 29
Study: 32950763

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic receptor antagonist)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salivary cortisol levels
Number of subjects: 24
Study: 36184697

Group type: EXPERIMENTAL
Intervention: Mepolizumab 24 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Reslizumab 0.8 mg/kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 33949213

Group type: EXPERIMENTAL
Intervention: High-altitude (HA) exposure
Number of subjects: 8
Study: 32089455

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFOX-4 (Arm A)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Bevacizumab plus XELOX-2 (Arm B)
Number of subjects: 132
Study: 34520429

Group type: EXPERIMENTAL
Intervention: Surgery alone (S)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy plus surgery (C+S)
Number of subjects: 367
Study: 33487014

Group type: EXPERIMENTAL
Intervention: P. cinnamomi, P. pini, and P. plurivora
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: P. pseudocryptogea
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: P. cambivora
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: P. plurivora (one isolate)
Number of subjects: 6
Study: 33192057

Group type: EXPERIMENTAL
Intervention: Pedometer-based physical activity coaching in addition to usual care
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74
Study: 616277889

Group type: COMPARATOR
Intervention: Corn oil (5 g/day; Placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day; Pio)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EPA+DHA concentrate (5 g/day, containing 2.8 g EPA+DHA; Omega-3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pioglitazone and EPA+DHA concentrate (PioOMEGA-3)
Number of subjects: 30
Study: 35972773

Group type: EXPERIMENTAL
Intervention: Male synthetic sling
Number of subjects: 380

Group type: COMPARATOR
Intervention: Artificial urinary sphincter
Number of subjects: 380
Study: 32276071

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg alcohol intake
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.02 g/kg alcohol intake (placebo)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Expectations related to alcohol intake
Number of subjects: 65
Study: 36451343

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 127

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (in patients with BM)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Erlotinib (in patients with BM)
Number of subjects: 127
Study: 33973233

Group type: EXPERIMENTAL
Intervention: Ofatumumab + Bendamustine
Number of subjects: 346

Group type: COMPARATOR
Intervention: Bendamustine
Number of subjects: 346
Study: 34353737

Group type: EXPERIMENTAL
Intervention: Insulin Resistance (IR)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Erythrocyte membrane fatty acid compositions
Number of subjects: 23
Study: 33788436

Group type: EXPERIMENTAL
Intervention: Acupuncture (lifting‐thrusting reinforcing and uniform reducing‐reinforcing methods) applied to specific acupuncture points for 20 min once daily for 3 months.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medication group taking Tripterygium Wilfordii Polyglycoside tablets (one tablet per time, 3 times a day) for 3 months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acupuncture group vs Medication group
Number of subjects: 30